Novartis, Eisai Sue Rivals Over Planned Banzel Generics

Law360, New York (July 25, 2013, 1:33 PM EDT) -- Eisai Inc. and Novartis Pharma AG on Wednesday sued five generic-drug makers in Delaware federal court, alleging their rivals’ planned versions of epilepsy treatment Banzel infringe three patents covering the drug.

According to the plaintiffs, the generic rufinamide tablets planned by their rivals — Glenmark Pharmaceuticals Ltd., Hetero Labs Ltd., Lupin Ltd., Mylan Pharmaceuticals Inc. and Roxane Laboratories Inc. — infringe U.S. Patent Numbers 6,740,669; 7,750,028; and 8,076,362, which are owned by Novartis and licensed to Eisai for use in the U.S.

“Plaintiffs will be irreparably...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Eisai Co. Ltd. et al. v. Lupin Ltd. et al.


Case Number

1:13-cv-01279

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

July 24, 2013


Case Title

Eisai Co. Ltd. et al v. Hetero Labs Ltd., et al.


Case Number

1:13-cv-01280

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

July 24, 2013


Case Title

Eisai Co. Ltd. et al. v. Lupin Ltd., et al.


Case Number

1:13-cv-01281

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

July 24, 2013


Case Title

Eisai Co. Ltd. et al. v. Mylan Pharmaceuticals Inc.


Case Number

1:13-cv-01282

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

July 24, 2013


Case Title

Eisai Co. Ltd. et al. v. Roxane Laboratories Inc.


Case Number

1:13-cv-01284

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

July 24, 2013

Law Firms

Companies

Government Agencies

Patents